Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 1/20 | 0.72 |
| ▸ | BACE1 | P56817 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | STAT3 | P40763 | 13/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oleoside Dimethyl Ester SCHEMBL21324467 | 0.95 | BACE1 (0.71) | IL2BACE1MAPTPOLBKDM4E | |
| Oleoside Dimethyl Ester SCHEMBL19831306 | 0.95 | BACE1 (0.71) | IL2BACE1MAPTPOLBKDM4E | |
| Oleoside Dimethyl Ester SCHEMBL29425902 | 0.95 | BACE1 (0.71) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL29426120 | 0.89 | IL2 (0.71) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL29425896 | 0.89 | IL2 (0.71) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL29426103 | 0.88 | BACE1 (0.68) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL23494908 | 0.87 | BACE1 (0.67) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL29425877 | 0.87 | BACE1 (0.67) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL23521505 | 0.87 | BACE1 (0.62) | IL2BACE1MAPTPOLBKDM4E | |
| SCHEMBL29426034 | 0.87 | BACE1 (0.67) | IL2BACE1MAPTPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702037-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024224085-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-109689077-B | Novel use and method | 纳图瑞克斯有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11590189-B2 | Therapeutic use of a Fraximus augustifolia extract | NATUREX S.A. (FR) | 2023-02-28 | — | — | US | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590189-B2 | Therapeutic use of a Fraximus augustifolia extract | FABP1, FXR1, FXR2 | IL2 4744/4885BACE1 3193/4885MAPT 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.